Information Provided By:
Fly News Breaks for July 18, 2017
BMRN, SRPT
Jul 18, 2017 | 11:25 EDT
Piper Jaffray analyst Edward Tenthoff said Sarepta's (SRPT) DMD license agreement with BioMarin (BMRN) "effectively ends" global patent litigation between the two and removes patent uncertainty for Sarepta, freeing the company to focus on drug commercialization and development. He keeps an Overweight rating and $43 price target on Sarepta shares.
News For SRPT;BMRN From the Last 2 Days
There are no results for your query SRPT;BMRN